Johnson & Johnson reports robust 2-year ICOTYDE results in plaque psoriasis

• Johnson & Johnson (NYSE:JNJ) reported two-year Phase 3 ICONIC-LEAD data showing at least 72% of ICOTYDE-treated patients achieved PASI 90 at Week 112.
• From Week 64 through Week 112, at least 70% achieved clear or almost clear skin, while 78% sustained meaningful itch improvement.
• Safety findings remained consistent with the established profile, with no new safety signals reported through Week 112.

Johnson & Johnson (NYSE:JNJ) reported two-year Phase 3 ICONIC-LEAD results showing at least 72% of ICOTYDE-treated patients achieved PASI 90 at Week 112.

The study enrolled 684 adults and adolescents aged 12 or older with moderate-to-severe plaque psoriasis, including 66 adolescent participants.

From Week 64 through Week 112, at least 70% achieved clear or almost clear skin, at least 44% achieved complete clearance by PASI and at least 46% achieved clear skin on investigator assessment.

Meaningful itch improvement was sustained in 78% of ICOTYDE-treated patients from Week 64 through Week 112.

Among PASI 90 responders who stopped treatment at Week 24, 85% regained that response within 24 weeks after restarting therapy.

Johnson & Johnson said safety findings through Week 112 remained consistent with ICOTYDE’s established profile, with no new safety signals identified.

ICOTYDE is already approved in the United States, Europe, Japan and China for use in plaque psoriasis.